|
Market Closed -
Nasdaq
16:00:00 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 37.97 USD | +1.39% |
|
-3.19% | -10.19% |
| 10-12 | UBS Initiates Coverage on Nektar Therapeutics With Neutral Rating, $53 Price Target | MT |
| 10-12 | Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NEKTAR THERAPEUTICS | Bio Therapeutic Drugs | +1.39% | -3.19% | -10.19% | -39.32% | -84.10% | 1.28B |  | | |
- Stock Market
- Stocks
- NKTR Stock
- Charts Nektar Therapeutics
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
